December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Raul Cordoba: Valemetostat for relapsed or refractory peripheral T-cell lymphoma
Nov 1, 2024, 17:17

Raul Cordoba: Valemetostat for relapsed or refractory peripheral T-cell lymphoma

Raul Cordoba shared on X:

Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.

Authors: Pier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, Stefan K Barta, Kenji Ishitsuka, Raul Córdoba, Shigeru Kusumoto, Emmanuel Bachy, Kate Cwynarski, Giuseppe Gritti, Anca Prica, Eric Jacobsen, Tatyana Feldman, Yann Guillermin,  Daisuke Ennishi, Dok Hyun Yoon, Eva Domingo Domenech, Jasmine Zain, Jie Wang, Jin Seok Kim, Marjolein van der Poel, Jin Jin, Sutan Wu, Yang Chen, Takaya Moriyama, Ai Inoue, Keiko Nakajima, Steven M Horwitz.

Raul Cordoba: Valemetostat for relapsed or refractory peripheral T-cell lymphoma

More posts featuring Raul Cordoba on oncodaily.com

Raúl Córdoba Mascuñano, MD, PhD is a specialist in hematology and hemotherapy. He is the Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit and Associate Chief of Hematology Department at Jiménez Díaz Foundation. He is the principal investigator for numerous clinical trials for non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia and other chronic lymphoproliferative syndromes. He is a member of the ethical review board at his current workplace.